*"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer"** into a more structured format:

---

### Abstract

#### Introduction
This study explores the efficacy and safety of combining ceralasertib (AZD6738) with durvalumab in advanced gastric cancer patients.

#### Methods
- **Design**: Open-label, single-center, non-randomized, phase II clinical trial.
- **Treatment**: Patients received ceralasertib (240 mg twice daily, days 15-28) with durvalumab (1500 mg, day 1 every 4 weeks).
- **Endpoints**: Primary endpoint was overall response rate (ORR). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety.

#### Results
- **Participants**: 53 patients enrolled.
- **ORR**: 22.6%.
- **DCR**: 58.1%.
- **PFS**: Median of 3.0 months.
- **OS**: Median of 6.7 months.
- **Safety**: Adverse events were manageable with dose modifications.

#### Biomarker Analysis
- **Findings**: Subgroup with loss of ATM expression and high HRD showed longer PFS.
- **Immune Response**: Upregulation of innate immune response and activation of intratumoral lymphocytes in responders.

#### Conclusion
The combination of ceralasertib and durvalumab demonstrated clinical activity and manageable safety in advanced gastric cancer, particularly benefiting patients with specific biomarker profiles